Systematic review finds levetiracetam linked to psychobehavioral adverse effects in epilepsy
Levetiracetam linked to irritability and aggression in epilepsy patients
This systematic review synthesizes evidence on psychobehavioral adverse effects (PBAEs) of levetiracetam in epilepsy. It reports mean rates …
A review finds levetiracetam for epilepsy is tied to higher rates of irritability and aggression, with some patients stopping the drug becau…
Review of emulated trial finds levetiracetam continuation associated with lower 90-day mortality after stroke
Taking This Common Stroke Medicine Might Save Lives After Discharge
This review summarizes an emulated target trial using Medicare claims (2008-2021) comparing continued versus discontinued outpatient levetir…
Older adults who kept taking a common seizure medication after a stroke had a lower risk of dying within three months.
FDA Approves Levetiracetam for Partial-Onset, Myoclonic, and Primary Generalized Tonic-Clonic Seizures
FDA approves a seizure medicine called levetiracetam for children and adults.
Levetiracetam is approved for the treatment of partial-onset seizures in patients 1 month and older, and as adjunctive therapy for myoclonic…
The FDA now approves levetiracetam for children as young as one month and adults to treat specific seizure types.